Figures
- Figure 1.
Updated treatment algorithm for patients with pulmonary arterial hypertension (PAH) in World Health Organization (WHO) functional class IV. ERA: endothelin receptor antagonist; PDE-5i: phosphodiesterase type-5 inhibitor; sGCS: soluble guanylate cyclase stimulators; BAS: balloon atrial septostomy. #: based on the WHO functional class of the majority of patients in the studies; ¶: morbidity and mortality were the primary end-point in a randomised controlled study or reduction in all-cause mortality (prospectively defined). Reproduced from [7] with permission from the publisher.
- Figure 2.
Use of parenteral prostanoids in 192 patients with pulmonary arterial hypertension (PAH) in functional class IV at the time of all-cause mortality. Results from the US REVEAL (Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management) registry. Data from [30].
Tables
- Table 1. Atrial septostomy improves haemodynamics in patients with pulmonary arterial hypertension
First author [ref.] Patients n Initial RAP mmHg RAP change LAP change Cardiac index change SOT change Rich [60] 6 17 41 NC 58 27 Nihill [61] 14 12 NC 36 9 Kerstein [62] 15 11 11 55 15 5 Sandoval [59] 15 15 29 55 35 22 Rothman [63] 12 23 22 20 24 18 Data are presented as %, unless otherwise stated. RAP: right atrial pressure; LAP: left atrial pressure; SOT: systemic organ transplant; NC: no change. Reproduced from [63] with permission from the publisher.
